The University of Chicago Joint Section of Hematology/Oncology at Mitchell Hospital and Michael Reese Hospital, Chicago, Illinois became a member of the Cancer & Leukemia Group B (CALGB) in 2/85, entered it's first patient on CALGB protocols 3/1/85, received NIH/NCI funding on 9/30/86, and entered 187 patients on group protocols by 6/1/87. Our current rate of accrual is 75-80 patients/year. The Joint Section has excellent cancer research facilities with 26 full-time faculty, 6 research associates, 6 private practitioners in oncology, 11 nurse oncologists and 13 fellows in addition to multiple laboratory technicians and secretaries. There are three in-patient units; a 24 bed hematology unit at The University of Chicago Medical Center (UCMC), a 24 bed oncology unit at UCMC, and a 36 bed hematology/oncology unit at Michael Reese Medical Center (MRMC). In addition, a data management unit exists at each medical center. We bring a long tradition of excellent independent research to the CALGB. In the past 2 years of CALGB membership, the Joint Section has expended considerable resources on CALGB activities. Nineteen of our 26 physicians have entered patients on protocols. Over 400 hours have been spent by section members directly on CALGB group wide activities. Larger number of hours have been spent by fellows, research nurses, and data managers coordinating patient entry. Chicago faculty members sit on 14 CALGB committees, chair 4 CALGB protocols, and will chair 4 additional protocols this year. Our laboratories in cytogenetics, molecular biology and hematopathology have fully supported and lead group activities. Our plans for the coming years include increasing patient accrual within the Joint Section to 100 patients/year by 1990 and adding several new adjunct institutions whose accrual by 1990 should total 30-40 patients/year. New initiatives in cytogenetics and gene mapping, molecular biology, pharmacology, biological response modifiers and high dose chemotherapy with autologous bone marrow protection are planned or in several cases have already been initiated. We plan to provide clinical leadership to the CALGB by means of protocol chairmanships in present and future studies. Lastly, our participation on the Board of Directors (Drs. Golomb and Schilsky) as well as the Leukemia (Dr. Golomb), Respiratory (Dr. Vogelzang), Chemotherapy (Drs. Schilsky and Ratain), Radiation Therapy (Ms. Grimmer), and Transplantation (Dr. Bitran) Committees will be major. Administrative support will be provided in the Oncology Nursing (Ms. Grimmer) Data Management (Ms. Skosey), Cancer Control (Dr. Hoffman), Data Audit (Dr. Vogelzang), and Cytogenetics Review (Dr. Le Beau) Committees.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Schools of Medicine
United States
Zip Code
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 224 publications